Midday movers: Netflix, Visa, Pfizer & More

CNBC
Midday movers: FMC, Meritor, Micros Systems & more
.

View photo

 

Take a look at some of Monday's midday movers:

Netflix (NFLX) moved higher after Oppenheimer upgraded its shares to outperform, saying the recent sell-off in the stock is overdone. Netflix is down some 25 percent from its highs a month ago.

Credit Suisse (Swiss Exchange: CSGN-CH) lost ground after it faced the threat of a new U.S. tax probe as New York state's top financial regulator requested documents from the Swiss bank.

Pfizer (PFE) fell despite some positive trial results for its breast cancer drug. Investors were hoping for better results from the study.

World Wrestling Entertainment (WWE) moved lower despite saying it's on track to getting a million subscribers by the end of 2014. Barron's said the company might not acquire enough subscribers to counteract the drop in pay per view event revenue.

Visa (NYSE:V) and MasterCard (MA) slid after Reuters said large retailers are muscling into the competitive mobile payment market. Zacks also reported that Russia has decided to have its own domestic payment system in six months, bypassing Visa and Mastercard, to become more self-dependent in the future.

MannKind (MNKD) fell after the FDA delayed its decision on the company's inhaled insulin treatment.

Vocus (VOCS) soared after it said it would be bought by private equity firm GTCR Valor Merger Sub for about $446 million, or $18 a share.

Hewlett-Packard (HPQ) gained ground after Barron's said the company's shares were poised to rise by 20 percent over the next year.

Qualcomm (QCOM)rose after the company gave details on its high-end smartphone chip, which is due to appear in smartphones in 2015.

Intel (INTC) moved higher after Pacific Crest upgraded the stock to outperform from sector perform, noting improving corporate PC demand.

ANN (ANN) moved lower after Oppenheimer downgraded the stock to perform, citing valuation.

Agios Pharmaceuticals (AGIO) advanced after its experimental leukemia drug showed promising activity in a trial.

(Read More: See CNBC's Market Insider Blog )

-By CNBC's Rich Fisherman.

Questions? Comments? Email us at marketinsider@cnbc.com

Rates

View Comments (0)